Literature DB >> 22295275

Dementia with lewy bodies: diagnosis and management for primary care providers.

Melanie Zupancic1, Aman Mahajan, Kamna Handa.   

Abstract

OBJECTIVE: The purpose of this review is to aid primary care providers in distinguishing dementia with Lewy bodies (DLB) from Alzheimer's disease and from Parkinson's disease with dementia. Differentiating these entities has important treatment implications. DATA SOURCES: A PubMed search was undertaken using the keywords Lewy body dementia, dementia with Lewy bodies, and Lewy body disease. There were no date restrictions. Only articles in the English language were reviewed. References of selected articles were reviewed for additional sources. DATA SELECTION AND EXTRACTION: Initially, 2,967 articles were retrieved. All 3 authors participated in data selection and extraction. Articles were further selected for content specific to epidemiology, clinical presentation, diagnostic studies, treatment, and prognosis. For articles with repetitive information, the most current article was used. This resulted in a total of 62 articles included in the review. DATA SYNTHESIS: Dementia with Lewy bodies is the second leading cause of dementia after Alzheimer's disease. The core symptoms of DLB, including cognitive fluctuations, visual hallucinations, and parkinsonism, may not always be present as a triad, and clinicians may be unaware of associated symptoms. Thus, this diagnosis is frequently missed by primary care providers. Often, DLB is misdiagnosed as Alzheimer's disease, Parkinson's disease, or a primary psychiatric illness. Treatments for DLB include cholinesterase inhibitors and N-methyl-D-aspartate antagonists. Antipsychotics should be avoided or used with caution.
CONCLUSIONS: Dementia with Lewy bodies is an often missed diagnosis. Symptoms are often attributed to other disorders. A high clinical suspicion is helpful in accurate diagnosis, and presence of any of the core symptoms should initiate clinical suspicion of DLB. Distinguishing DLB from other disorders has important treatment implications.

Entities:  

Year:  2011        PMID: 22295275      PMCID: PMC3267516          DOI: 10.4088/PCC.11r01190

Source DB:  PubMed          Journal:  Prim Care Companion CNS Disord        ISSN: 2155-7780


  67 in total

1.  Predictors of survival in dementia with lewy bodies and Parkinson dementia.

Authors:  Kurt A Jellinger; Gregor K Wenning; Klaus Seppi
Journal:  Neurodegener Dis       Date:  2007-10-09       Impact factor: 2.977

2.  Efficacy and safety of galantamine in patients with dementia with Lewy bodies: a 24-week open-label study.

Authors:  Keith Edwards; Donald Royall; Linda Hershey; David Lichter; Ann Hake; Martin Farlow; Florence Pasquier; Stewart Johnson
Journal:  Dement Geriatr Cogn Disord       Date:  2007-04-03       Impact factor: 2.959

3.  Long-Term use of rivastigmine in patients with dementia with Lewy bodies: an open-label trial.

Authors:  J Grace; S Daniel; T Stevens; K K Shankar; Z Walker; E J Byrne; S Butler; D Wilkinson; J Woolford; J Waite; I G McKeith
Journal:  Int Psychogeriatr       Date:  2001-06       Impact factor: 3.878

4.  EEG comparisons in early Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease with dementia patients with a 2-year follow-up.

Authors:  Laura Bonanni; Astrid Thomas; Pietro Tiraboschi; Bernardo Perfetti; Sara Varanese; Marco Onofrj
Journal:  Brain       Date:  2008-01-17       Impact factor: 13.501

5.  L-dopa responsiveness in dementia with Lewy bodies, Parkinson disease with and without dementia.

Authors:  S B Bonelli; G Ransmayr; M Steffelbauer; T Lukas; C Lampl; M Deibl
Journal:  Neurology       Date:  2004-07-27       Impact factor: 9.910

Review 6.  Three years survival in patients with a clinical diagnosis of dementia with Lewy bodies.

Authors:  Z Walker; R L Allen; S Shergill; E Mullan; C L Katona
Journal:  Int J Geriatr Psychiatry       Date:  2000-03       Impact factor: 3.485

Review 7.  The clinical and pathophysiological relevance of REM sleep behavior disorder in neurodegenerative diseases.

Authors:  Alex Iranzo; Joan Santamaria; Eduard Tolosa
Journal:  Sleep Med Rev       Date:  2009-04-10       Impact factor: 11.609

8.  A multifactorial intervention to reduce the risk of falling among elderly people living in the community.

Authors:  M E Tinetti; D I Baker; G McAvay; E B Claus; P Garrett; M Gottschalk; M L Koch; K Trainor; R I Horwitz
Journal:  N Engl J Med       Date:  1994-09-29       Impact factor: 91.245

Review 9.  Dementia with Lewy bodies.

Authors:  David Weisman; Ian McKeith
Journal:  Semin Neurol       Date:  2007-02       Impact factor: 3.420

10.  Cholinesterase inhibitors reduce cortical Abeta in dementia with Lewy bodies.

Authors:  C G Ballard; K A Chalmers; C Todd; I G McKeith; J T O'Brien; G Wilcock; S Love; E K Perry
Journal:  Neurology       Date:  2007-05-15       Impact factor: 9.910

View more
  8 in total

1.  Dementia: What pharmacists need to know.

Authors:  Silvia Duong; Tejal Patel; Feng Chang
Journal:  Can Pharm J (Ott)       Date:  2017-02-07

2.  Synuclein Motor Dysfunction Composite Scale for the Discrimination of Dementia With Lewy Bodies From Alzheimer's Disease.

Authors:  Ying-Tsung Chen; Satoshi Orimo; Cheng-Yu Wei; Guang-Uei Hung; Shieh-Yueh Yang; Pai-Yi Chiu
Journal:  Front Aging Neurosci       Date:  2022-05-19       Impact factor: 5.702

3.  Current electroconvulsive therapy practice and research in the geriatric population.

Authors:  Nancy Kerner; Joan Prudic
Journal:  Neuropsychiatry (London)       Date:  2014-02

Review 4.  Dementia with Lewy bodies - from scientific knowledge to clinical insights.

Authors:  Nikitas A Arnaoutoglou; John T O'Brien; Benjamin R Underwood
Journal:  Nat Rev Neurol       Date:  2019-02       Impact factor: 42.937

Review 5.  Lipocalin 2 regulates iron homeostasis, neuroinflammation, and insulin resistance in the brains of patients with dementia: Evidence from the current literature.

Authors:  Daejin Lim; Jae-Ho Jeong; Juhyun Song
Journal:  CNS Neurosci Ther       Date:  2021-05-04       Impact factor: 5.243

Review 6.  Ethnopharmacological Approaches for Dementia Therapy and Significance of Natural Products and Herbal Drugs.

Authors:  Devesh Tewari; Adrian M Stankiewicz; Andrei Mocan; Archana N Sah; Nikolay T Tzvetkov; Lukasz Huminiecki; Jarosław O Horbańczuk; Atanas G Atanasov
Journal:  Front Aging Neurosci       Date:  2018-02-12       Impact factor: 5.750

7.  Quantitative electroencephalography as a marker of cognitive fluctuations in dementia with Lewy bodies and an aid to differential diagnosis.

Authors:  Myrto Stylianou; Nicholas Murphy; Luis R Peraza; Sara Graziadio; Ruth Cromarty; Alison Killen; John T O' Brien; Alan J Thomas; Fiona E N LeBeau; John-Paul Taylor
Journal:  Clin Neurophysiol       Date:  2018-04-03       Impact factor: 3.708

8.  Confirmation of 123I-FP-CIT SPECT Quantification Methods in Dementia with Lewy Bodies and Other Neurodegenerative Disorders.

Authors:  Daniela D Maltais; Lennon G Jordan; Hoon-Ki Min; Toji Miyagawa; Scott A Przybelski; Timothy G Lesnick; Robert R Reichard; Dennis W Dickson; Melissa E Murray; Kejal Kantarci; Bradley F Boeve; Val J Lowe
Journal:  J Nucl Med       Date:  2020-03-20       Impact factor: 11.082

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.